Mergers & AcquisitionsMediumUpdated×2•Originally published 4 November 2026•Updated 5 November 2026•
1 min read
Rhythm Pharmaceuticals Jumps 28% on AstraZeneca $124 Per-Share Buyout Bid
Key Facts
1AstraZeneca has made a roughly $10 billion offer to acquire Rhythm Pharmaceuticals.
2The potential deal aims to expand AstraZeneca's portfolio of rare disease treatments.
Rhythm Pharmaceuticals stock surged 28% following reports that AstraZeneca has made an offer of $124 per share to acquire the company. The Wall Street Journal reported that the deal, valued at approximately $10 billion, aims to expand AstraZeneca's portfolio of rare disease treatments.
AZN was trading at $189.45 on November 4, 2026. Meanwhile, RYTM shares saw a sharp rally after closing at $86.44 on November 3, 2026, as the $124 per-share bid represents a significant premium in AstraZeneca's move to bolster its specialized medical pipeline.